These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699 [TBL] [Abstract][Full Text] [Related]
4. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB Pike E; Grafinger KE; Cannaert A; Ametovski A; Luo JL; Sparkes E; Cairns EA; Ellison R; Gerona R; Stove CP; Auwärter V; Banister SD Drug Test Anal; 2021 Jul; 13(7):1383-1401. PubMed ID: 33787091 [TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice. Glatfelter GC; Partilla JS; Baumann MH Neuropsychopharmacology; 2022 Mar; 47(4):924-932. PubMed ID: 34802041 [TBL] [Abstract][Full Text] [Related]
6. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Cabanlong CV; Russell LN; Fantegrossi WE; Prather PL Toxicol Sci; 2022 Apr; 187(1):175-185. PubMed ID: 35201352 [TBL] [Abstract][Full Text] [Related]
7. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157 [TBL] [Abstract][Full Text] [Related]
8. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor. Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L ACS Chem Neurosci; 2023 Nov; 14(21):3928-3940. PubMed ID: 37847546 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Banister SD; Adams A; Kevin RC; Macdonald C; Glass M; Boyd R; Connor M; McGregor IS; Havel CM; Bright SJ; Vilamala MV; Lladanosa CG; Barratt MJ; Gerona RR Drug Test Anal; 2019 Feb; 11(2):279-291. PubMed ID: 30151911 [TBL] [Abstract][Full Text] [Related]
10. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. Grafinger KE; Vandeputte MM; Cannaert A; Ametovski A; Sparkes E; Cairns E; Juchli PO; Haschimi B; Pulver B; Banister SD; Stove CP; Auwärter V Drug Test Anal; 2021 Jul; 13(7):1412-1429. PubMed ID: 33908179 [TBL] [Abstract][Full Text] [Related]
11. Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. Ametovski A; Macdonald C; Manning JJ; Haneef SAS; Santiago M; Martin L; Sparkes E; Reckers A; Gerona RR; Connor M; Glass M; Banister SD ACS Chem Neurosci; 2020 Nov; 11(21):3672-3682. PubMed ID: 33054155 [TBL] [Abstract][Full Text] [Related]
12. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice. Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953 [TBL] [Abstract][Full Text] [Related]
14. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists. Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898 [TBL] [Abstract][Full Text] [Related]
15. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists. Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383 [TBL] [Abstract][Full Text] [Related]
16. Using in vitro receptor activity studies of synthetic cannabinoids to support the risk assessment of new psychoactive substances - A Swedish strategy to protect public health from harm. Bäckberg M; Vikingsson S; Strandberg J; Wall S; Åstrand A; Karlsson H; Persson M; Kronstrand R; Green H Forensic Sci Int; 2023 Jul; 348():111691. PubMed ID: 37116244 [TBL] [Abstract][Full Text] [Related]